Disease relevance of C13177

• We describe the blood supply of the cervical spinal cord and suggest that this infarction resulted from an impaired perfusion of the major feeding anterior radicular artery of the spinal cord, after local injection of iotrolan, bupivacaine, and triamcinolon-hexacetonide around the C6-nerve root on the right side [1].
• Iotrolan induced no inflammatory reaction in the abdomen, whereas Lipiodol induced a marked abdominal inflammatory reaction, including granuloma formation [2].
• Aseptic meningitis complicating iotrolan myelography [3].
• Encephalopathy and rhabdomyolysis induced by iotrolan during epiduroscopy: [Encephalopathie et rhabdomyolyse provoquees par l'iotrolan durant l'epiduroscopie] [4].
• Post-ERCP pancreatitis was diagnosed in 2 patients in the iopromid group and in 5 patients in the iotrolan group [5].

Psychiatry related information on C13177

• Intracranial iotrolan distribution following cervical myelography. Postmyelographic registration of adverse effects, psychometric assessment and electroencephalographic recording [6].

High impact information on C13177

• RESULTS: In the IPRK, diatrizoate and iotrolan reduced the glomerular filtration rate and renal perfusate flow, an effect markedly inhibited by bosentan (n = 6 per group) [7].
• Knee arthrography: comparison of iotrolan and ioxaglate sodium meglumine [8].
• Arthrographic image quality and relative morbidity resulting from use of the nonionic dimer iotrolan and the ionic dimer ioxaglate sodium meglumine were compared in a prospective double-blind study performed in 80 patients [8].
• Iotrolan demonstrated better image quality on serial radiographs in knee joints without previous effusions [8].
• In a prospective, randomized, double-blind study, 49 patients underwent lumbar myelography using iotrol (24 patients) or metrizamide (25 patients) [9].

Chemical compound and disease context of C13177

• Intra-articular injection of amidotrizoate, iopamidol, iotrol and sorbitol caused early, mild and transient histological changes of the synovium (synovial hyperplasia, infiltration by leucocytes) [10].
• RESULTS: Of 13 injections with each contrast medium, ioxaglate induced ventricular fibrillation in 11 after 34 +/- 5 sec, iotrolan in 6 after 42 +/- 4 sec, and iodixanol in 3 after 61 +/- 1 sec [11].
• After epidural injections of iotrolan and mepivacaine, he developed motor weakness and hypoesthesia in both legs, which lasted for three hours [4].
• When Ppa was raised by acute hypoxia, ioxaglate and diatrizoate (0.5 ml) caused a fall in Ppa (percentage fall -53+/-23 and -118+/-10, respectively, p<0.001) while iotrolan and iopromide caused a small further rise in Ppa, which was significant with iotrolan at a dose of 0.3 ml (percentage rise in pressure 14.2+/-2.3, p<0.05) [12].

Biological context of C13177

• The intravenous LD50 of DL-3-117 in mice was 26 g/kg, and in rats it was 12.7 g/kg [13].
• Safety and pharmacokinetics of iotrolan in hysterosalpingography. Retention and irritability compared with Lipiodol [2].
• RATIONALE AND OBJECTIVES: To investigate whether the lower incidence of vasodilatation upon vascular injection of iotrolan, as compared with monomeric contrast media, is solely the result of its isotonicity [14].
• With iotrolan, no significant reduction in chemotaxis was seen at 30 minutes or at 24 hours [15].
• Tissue distribution and excretion of iotrolan after intravenous and suboccipital injections in animals [16].

Anatomical context of C13177

• A dose of 300 mg I/kg injected into a permanently cannulated lateral ventricle produced neurofunctional deficits with all contrast media except DL-3-117, which scored equal to Ringer's solution [13].
• On the basis of these findings, iotrol holds promise as a clinical contrast material for the subarachnoid space [17].
• Following animal sacrifice, histologic examination of the synovium revealed a significant difference in the inflammatory response evoked by the contrast agents: Iotrol caused less inflammation [18].
• Iotrol is cleared from the cerebrospinal fluid and excreted by glomerular filtration within the same time range as other water-soluble contrast media [19].
• Both osmolarity and chemotoxicity contribute to the greater vasorelaxant effect on swine renal artery of monomeric contrast media when compared to that of the nonionic dimeric contrast medium, iotrolan [14].

Associations of C13177 with other chemical compounds

• The lethal dose (LD50) in protozoa was 320 mg I/ml for DL-3-117, 96 mg I/ml for metrizamide, and 101 mg I/ml for iopamidol [13].
• Animal experimental myelography in the pig. A comparison between iohexol and iotrolan [20].
• In anesthetized animals, caudal mesenteric veins were exposed and perfused with the ionic contrast medium, diatrizoate, and the nonionic contrast media iopromide and iotrolan for 2 minutes at 5 mL/minute [21].
• Effects of dimeric radiographic contrast medium iotrolan on Swine renal arteries: comparison with monomeric contrast media iohexol and iomeprol [14].
• Histamine significantly decreased after iotrolan injection and C5a increased 6 hours (P>0.05) after CM administration in parallel to IL-6 [22].

Gene context of C13177

• Iotrol, a new myelographic agent: 1. Radiography, CT, CSF clearance, and brain penetration [23].
• We did not observe statistically significant differences in comparing iotrolan and iopromid concerning ERCP/EST-induced pancreatic damage [5].
• The rare finding of strong periventricular enhancement was observed by means of intraoperative CT cisternography using Iotrolan in a one-month-old boy with Dandy-Walker syndrome associated with occipital cephalocele [24].

Analytical, diagnostic and therapeutic context of C13177

• Bronchography with iotrolan 300 [25].
• Use of iotrolan versus ethiodized poppy-seed oil in hysterosalpingography [26].
• Suitability of and tolerance to Iotrolan 300 in bronchography via the fibreoptic bronchoscope [27].
• Computed tomography values of splenic and hepatic sections, 1 hour after intravenous injection of Iotrolan MREV (500 mgI/kg), are 0.78, and 0.08 Hounsfield Units (HU)/mgI/kg, respectively (versus 0.01, and 0.006 HU/mgI/kg for free Iotrolan) [28].
• Iotrol, a new nonionic, water-soluble, hexiodinated dimeric contrast medium for myelography, was used in clinical trials in 29 patients [19].

References